CD BioGlyco is a leader in the field of glycomedicine development. Our team has developed a comprehensive glycomedicine development platform focused on solving difficulties and problems in glycomedicine research and development. We are confident to be your indispensable research assistant in the field of glycobiology.
According to the sources of carbohydrates, our services include plant-derived, animal-derived, microbial-derived, and synthetic carbohydrate-based glycomedicine development. Depending on the types of carbohydrates, our services include monosaccharide, disaccharide, trisaccharide, oligosaccharide, polysaccharide, glycoside, and glycopeptide-based glycomedicine development. Depending on the applications, we offer the development of anticoagulant, cardiovascular, antitumor, antidiabetic, antibacterial, antiviral, and antiparasitic glycomedicines. According to the strategies, we develop glycomedicine targeting the interaction of lectins and carbohydrates, targeting carbohydrates of specific pathogens, or targeting carbohydrate changes in diseases.
In addition, we also provide glycoengineering-based protein and antibody drug development services for global customers.
In recent years, more and more researchers have utilized the function of carbohydrates to develop biopharmaceuticals. CD BioGlyco develops protein and antibody drugs by modifying carbohydrates with Glycoengineering methods.
CD BioGlyco is committed to providing high-quality carbohydrate-based glycomedicine development services. If you have special needs in glycomedicine development, please feel free to contact us for more information.
References:
